Niagen Bioscience Inc

NAGE

Add to Watchlist

3.705USD

-0.095-2.51%

Market hours （ET）Quotes delayed by 15 min

Niagen Bioscience Inc's Score

Industry at a Glance

Industry Ranking

69 / 382

Overall Ranking

177 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Niagen Bioscience Inc Highlights

StrengthsRisks

Niagen Bioscience, Inc., formerly Chromadex Corp., is a global bioscience company. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. The Company’s Consumer Products segment provides finished dietary supplement products that contain the Company's proprietary ingredients directly to consumers and distributors and offers NAD+ test kits exclusively to healthcare practitioners. The Ingredients segment develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and United States FDA-registered 503B outsourcing facilities, respectively. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 54.87% year-on-year.

Fairly Valued

The company’s latest PE is 16.27, at a medium 3-year percentile range.

Held by Invesco

Star Investor Invesco holds 19.64K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.03.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

12.600

Target Price

+235.11%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Niagen Bioscience Inc is 8.67, ranking 28 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 31.47M, representing a year-over-year increase of 3.26%, while its net profit experienced a year-over-year increase of 24.79%.

Score

Industry at a Glance

Previous score

8.67

Change

0



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.11

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.73

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.49

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Niagen Bioscience Inc is 5.53, ranking 365 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is 16.27, which is 285.43% below the recent high of 62.72 and 68.17% above the recent low of 5.18.

Score

Industry at a Glance

Previous score

5.53

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 69/382

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Niagen Bioscience Inc is 8.80, ranking 52 out of 382 in the Biotechnology & Medical Research industry. The average price target is 14.00, with a high of 23.00 and a low of 12.00.

Score

Industry at a Glance

Previous score

8.80

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Niagen Bioscience Inc is 6.77, ranking 185 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 4.71 and the support level at 3.30, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.72

Change

0.05

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-14

The current institutional shareholding score of Niagen Bioscience Inc is 3.00, ranking 193 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 38.95%, representing a quarter-over-quarter decrease of 23.33%. The largest institutional shareholder is James Simons, holding a total of 914.12K shares, representing 1.15% of shares outstanding, with 72.84% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Brilliant Dynasty Ltd

11.41M

--

Pioneer Step Holdings, Ltd.

6.92M

--

BlackRock Institutional Trust Company, N.A.

3.53M

+1.23%

Black Sheep, FLP

2.08M

--

Tieton Capital Management, LLC

1.65M

-0.11%

Fried (Robert N)

1.65M

+4.22%

Arrowstreet Capital, Limited Partnership

1.62M

+12.52%

UBS Financial Services, Inc.

1.41M

+18.03%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Niagen Bioscience Inc is 6.03, ranking 29 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 2.21. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Niagen Bioscience Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Niagen Bioscience Inc

NAGE

7.01 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.66 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.61 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Exelixis Inc

EXEL

8.49 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.48 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment